See What HealthDay Can Do For You
Contact Us

Two Arthritis Drugs Found to be Cost-Effective

Etanercept, adalimumab are more so than infliximab for rheumatoid arthritis patients

TUESDAY, April 22 (HealthDay News) -- The tumor necrosis factor (TNF) inhibitors etanercept and adalimumab are more likely to be cost-effective for treating rheumatoid arthritis in the Medicare population than infliximab, according to research published in the April Arthritis & Rheumatism.

Allan J. Wailoo, Ph.D., of the University of Sheffield in Sheffield, United Kingdom, and colleagues developed a model to compare the costs and quality-adjusted life years of etanercept, adalimumab, anakinra and infliximab, which can be considered standard treatment under Medicare Part B. The researchers used data from a meta-analysis of randomized controlled trials as well as from a database of patient self-reported information.

According to their work, anakinra is the least costly but also least effective option. Etanercept and adalimumab were roughly equal in effectiveness to infliximab but at a lower cost.

"Future work that considers sequential biologic use, early cessation of treatment in poor responders, and subgroup analyses will be valuable in identifying the most cost-effective use of biologic DMARDs (disease-modifying anti-rheumatic drugs) in the Medicare population. With the recent licensing of abatacept and rituximab, the latter of which is licensed for use after a TNF inhibitor has failed, assessment of the cost-effectiveness of sequential strategies is likely to be particularly important," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.